share_log

默克斥资高达20亿美元买下翰森制药一款在研减肥药全球权益

Merck invested as much as 2 billion dollars to acquire the global rights to a weight loss drug under development by HANSOH PHARMA.

Global market news report. ·  Dec 19 01:00

Merck has acquired a potential drug in the emerging weight loss market for up to 2 billion dollars.

Merck announced on Wednesday that under the terms of the agreement, the company will obtain global exclusive rights for the development, production, and commercialization of HS-10535 from Chinese pharmaceutical company HANSOH PHARMA, which is an experimental oral drug targeting GLP-1 receptors.

bigMerck

Merck will pay HANSOH PHARMA an upfront payment of 0.112 billion dollars and may additionally pay milestone payments of 1.9 billion dollars.

This news led to a decline of 11% and 13% for two biotechnology companies developing weight loss drugs, Viking Therapeutics Inc. and Structure Therapeutics Inc., respectively, during early trading in New York on Wednesday, as investors speculated that the potential deal with Merck was no longer in existence. Merck's stock price remained stable.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment